Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the most promising growth stocks according to analysts.

Cannabis advocates are hoping bills for expanded cannabis use and possession will advance in this year’s legislative session.

Cannabis advocates are hoping bills for expanded cannabis use and possession will advance in this year’s legislative session.

Kaylin Gawf, a 28-year-old mom to daughter Jace, 9, and son, Memphis, 6, launched a GoFundMe to pay for her funeral and ...

Kaylin Gawf, a single mom from Oklahoma, is planning her own funeral and raising money for her kids before her death, ...

Shares of Xeris Biopharma Holdings gained after the company raised its revenue guidance for 2025, driven by the performance of its Recorlev treatment. The stock rose 9.5% to $7.90 on Thursday. Shares ...

Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL" ...

Who's Line Is It Anyway?'s long-running performer—was diagnosed with a detached retina, prompting him to seek emergency eye ...

Dechra announced earlier today that it has received approval from the FDA for its pergolide tablets (Zygolide; Dechra) to ...

The FDA has approved pergolide tablets (Zygolide; Dechra) for controlling clinical signs associated with pituitary pars intermedia dysfunction (PPID) in horses, also known as equine Cushing disease.

Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.